Nasus Pharma (NSRX) Current Deferred Tax Assets (2024 - 2025)

Nasus Pharma (NSRX) reported Current Deferred Tax Assets of $348000.0 for Q2 2025, up 33.85% quarter-over-quarter from $260000.0 in Q4 2024.

Nasus Pharma (NSRX) Current Deferred Tax Assets (2024 - 2025) Analysis & Trends

Nasus Pharma has reported Current Deferred Tax Assets for 2 years, with the latest figure at $348000.0 in Q2 2025.

For the quarter ending Q2 2025, Current Deferred Tax Assets changed N/A year-over-year to $348000.0; the trailing twelve-month figure through Jun 2025 stood at $348000.0 (changed N/A YoY), and the FY2024 full-year result was $260000.0, changed N/A from the prior year.
Current Deferred Tax Assets for Q2 2025 stood at $348000.0, up from $260000.0 in the prior quarter.
The five-year high for Current Deferred Tax Assets was $348000.0 in Q2 2025, with the low at $260000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Gsk	93,699,046.73 Bn	93,699,041.77 Bn	7.76 Bn
2	Eli Lilly	1,012.06 Bn	1,006.77 Bn	16.22 Bn
3	Johnson & Johnson	560.67 Bn	538.62 Bn	15.96 Bn
4	AbbVie	402.20 Bn	392.85 Bn	10.78 Bn
5	Merck	298.59 Bn	292.94 Bn	12.09 Bn
6	Amgen	188.77 Bn	176.74 Bn	5.87 Bn
7	Gilead Sciences	160.22 Bn	152.49 Bn	5.52 Bn
8	Pfizer	148.19 Bn	135.42 Bn	-1.21 Bn
9	Bristol Myers Squibb	116.72 Bn	106.26 Bn	8.07 Bn
10	Nasus Pharma	23.47 Mn	19.18 Mn	-

Download Data